Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Howell

Showing results (221-230 of 339) with videos related to

Pageof 34
Sort By:
Journal of Medical Genetics|November 19, 2025
Validation of the pathology-adjusted Manchester scoring system in over 10 000 assessments of cases with breast and/or ovarian cancerD Gareth Evans, Robert D Morgan, Claire Forde, et al.
Breast Cancer Research and Treatment|March 16, 2012
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patientsRoberta Ferraldeschi, Monica Arnedos, Kristen D Hadfield, et al.
JAMA Oncology|January 19, 2018
Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk PredictionElke M van Veen, Adam R Brentnall, Helen Byers, et al.
Cell Cycle (Georgetown, Tex.)|September 1, 2012
CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesisClaudia Capparelli, Barbara Chiavarina, Diana Whitaker-Menezes, et al.
Oncotarget|February 12, 2015
Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restrictionRebecca Lamb, Hannah Harrison, Duncan L Smith, et al.
Lancet (London, England)|December 17, 2013
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialJack Cuzick, Ivana Sestak, John F Forbes, et al.
Breast Cancer Research : BCR|December 4, 2014
Risk determination and prevention of breast cancerAnthony Howell, Annie S Anderson, Robert B Clarke, et al.
Pilot and Feasibility Studies|December 21, 2021
Testing a breast cancer prevention and a multiple disease prevention weight loss programme amongst women within the UK NHS breast screening programme-a randomised feasibility studyMichelle Harvie, David P French, Mary Pegington, et al.
Endocrine-Related Cancer|July 20, 2007
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction modelRichard J Santen, Norman F Boyd, Rowan T Chlebowski, et al.
Cell Cycle (Georgetown, Tex.)|November 23, 2012
BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapiesUbaldo E Martinez-Outschoorn, Renee Balliet, Zhao Lin, et al.
Pageof 34

Showing results (221-230 of 339) with videos related to

Sort By:
Pageof 34
Journal of Medical Genetics|November 19, 2025
Validation of the pathology-adjusted Manchester scoring system in over 10 000 assessments of cases with breast and/or ovarian cancerD Gareth Evans, Robert D Morgan, Claire Forde, et al.
Breast Cancer Research and Treatment|March 16, 2012
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patientsRoberta Ferraldeschi, Monica Arnedos, Kristen D Hadfield, et al.
JAMA Oncology|January 19, 2018
Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk PredictionElke M van Veen, Adam R Brentnall, Helen Byers, et al.
Cell Cycle (Georgetown, Tex.)|September 1, 2012
CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesisClaudia Capparelli, Barbara Chiavarina, Diana Whitaker-Menezes, et al.
Oncotarget|February 12, 2015
Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restrictionRebecca Lamb, Hannah Harrison, Duncan L Smith, et al.
Lancet (London, England)|December 17, 2013
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialJack Cuzick, Ivana Sestak, John F Forbes, et al.
Breast Cancer Research : BCR|December 4, 2014
Risk determination and prevention of breast cancerAnthony Howell, Annie S Anderson, Robert B Clarke, et al.
Pilot and Feasibility Studies|December 21, 2021
Testing a breast cancer prevention and a multiple disease prevention weight loss programme amongst women within the UK NHS breast screening programme-a randomised feasibility studyMichelle Harvie, David P French, Mary Pegington, et al.
Endocrine-Related Cancer|July 20, 2007
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction modelRichard J Santen, Norman F Boyd, Rowan T Chlebowski, et al.
Cell Cycle (Georgetown, Tex.)|November 23, 2012
BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapiesUbaldo E Martinez-Outschoorn, Renee Balliet, Zhao Lin, et al.
Pageof 34